Technetium Tc 99m tilmanocept



Drug updated on 4/24/2024

Dosage FormInjection (intradermal, subcutaneous, subareolar, or peritumoral; 92.5 MBq (2.5 mCi) and 250 mcg of technetium Tc 99m tilmanocept)
Drug ClassRadioactive diagnostic agents
Ongoing and
Completed Studies


  • Indicated with or without scintigraphic imaging for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in adult and pediatric patients age one month and older with solid tumors for which this procedure is a component of intraoperative management.
  • Indicated with or without scintigraphic imaging for lymphatic guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Technetium Tc 99m tilmanocept (Lymphoseek) is indicated for lymphatic mapping and sentinel lymph node biopsy in patients with solid tumors, including those with clinically node-negative squamous cell carcinoma of the oral cavity, breast cancer, or melanoma. It has a low molecular weight and specific affinity for mannose receptors present on lymphatic reticuloendothelial cells.
  • The information was derived from one systematic review/meta-analysis that examined technetium Tc 99m tilmanocept's effectiveness and safety across different types of cancer.
  • This drug demonstrates high preoperative and intraoperative detection rates for identifying at least one sentinel node across evaluated cancers: 1. Breast cancer: 0.94 preoperatively and 0.99 intraoperatively.
  • Melanoma: 0.98 preoperatively and 1.00 intraoperatively.
  • Head and neck cancer: 0.97 preoperatively and 0.99 intraoperatively.
  • For melanoma specifically, the pooled sensitivity for detecting nodal metastasis was notably high at 0.97, indicating a strong diagnostic performance in identifying patients with nodal metastases.
  • Compared to other radiotracers used, technetium Tc 99m tilmanocept appears highly effective but requires further multicenter trials to conclusively determine its superiority over others regarding effectiveness and safety.
  • Although no distinct outcomes were specified within patient subgroups beyond broad categories such as breast cancer or head/neck cancers, it suggests the potential need for more research into understanding how this drug performs across various demographics or clinical subgroups within these categories.

Product Monograph / Prescribing Information

Document TitleYearSource
Lymphoseek (technetium Tc 99m tilmanocept) Prescribing Information.2021Cardinal Health 414, LLC Dublin, OH

Systematic Reviews / Meta-Analyses